The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma

Yu Fon Chen, Chien Hsiang Chang, Zih Ning Huang, Yu Chu Su, Sue Joan Chang, Jeng Shiung Jan

研究成果: Article同行評審

8 引文 斯高帕斯(Scopus)

摘要

Epstein-Barr virus (EBV) infection is associated with B cell lymphomas in humans. The latent membrane protein 1 (LMP-1) of EBV constitutively activates the JAK/STAT signaling pathway and contributes to the proliferation of EBV-infected primary human B lymphocytes. Thus, targeting LMP1-induced JAK/STAT signaling may prove effective in treating B-cell lymphomas. The extract of the fruiting body of Antrodia cinnamomea, has been reported to have cytotoxicity on blood cancer cells. Here, we report that the bioactivity of antcin H, an analog of the JAK2 inhibitor zhankuic acid A (ZAA), inhibits LMP1-induced JAK/STAT related signaling and induces lymphoma cell line apoptosis. Moreover, antcin H enhances low-dose methotrexate (MTX) cytotoxicity against lymphoma cells. Treatment of antcin H with low-dose MTX significantly suppressed tumor growth and prolonged the survival of tumor-bearing mice. Our findings indicate antcin H as a potential therapeutic agent for the treatment of EBV-infected cancer cells.

原文English
頁(從 - 到)1193-1203
頁數11
期刊Leukemia and Lymphoma
60
發行號5
DOIs
出版狀態Published - 2019 四月 16

All Science Journal Classification (ASJC) codes

  • 血液學
  • 腫瘤科
  • 癌症研究

指紋

深入研究「The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma」主題。共同形成了獨特的指紋。

引用此